anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND & AIMS: Serum prealbumin is considered to be a sensitive predictor of clinical outcomes and a quality marker for nutrition support. However, its susceptibility to inflammation restricts its usage in critically ill patients according to current guidelines. We assessed the performance of the initial value of prealbumin and dynamic changes for predicting the ICU mortality and the effectiveness of nutrition support in critically ill patients.
METHODS: This monocentric study included patients admitted to the ICU between 2009 and 2016, having at least one initial prealbumin value available. Prospectively recorded data were extracted from the electronic ICU charts. We used both univariable and multivariable logistic regressions to estimate the performance of prealbumin for the prediction of ICU mortality. Additionally, the association between prealbumin dynamic changes and nutrition support was assessed via a multivariable linear mixed-effects model and multivariable linear regression. Performing subgroup analysis assisted in identifying patients for whom prealbumin dynamic assessment holds specific relevance.
RESULTS: We included 3136 patients with a total of 4942 prealbumin levels available. Both prealbumin measured at ICU admission (adjusted odds-ratio (aOR) 0.04, confidence interval (CI) 95% 0.01-0.23) and its change over the first week (aOR 0.02, CI 95 0.00-0.19) were negatively associated with ICU mortality. Throughout the entire ICU stay, prealbumin dynamic changes were associated with both cumulative energy (estimate: 33.2, standard error (SE) 0.001, p < 0.01) and protein intakes (1.39, SE 0.001, p < 0.01). During the first week of stay, prealbumin change was independently associated with mean energy (6.03e-04, SE 2.32e-04, p < 0.01) and protein intakes (1.97e-02, SE 5.91e-03, p < 0.01). Notably, the association between prealbumin and energy intake was strongest among older or malnourished patients, those suffering from increased inflammation and those with high disease severity. Finally, prealbumin changes were associated with a positive mean nitrogen balance at day 7 only in patients with SOFA <4 (p = 0.047).
CONCLUSION: Prealbumin measured at ICU admission and its change during the first-week serve as an accurate predictor of ICU mortality. Prealbumin dynamic assessment may be a reliable tool to estimate the effectiveness of nutrition support in the ICU, especially among high-risk patients.
PURPOSE:To prepare the lipidal microsome excellent in storage stability and biodegradability and excellent in the sustained release property of a substance, e.g. a medicine, contained in an internal water phase as a lipidal microsome for liposome. CONSTITUTION:The material for forming the lipidal microsome comprises (A) a non-polymerizable phospholipid, and (B) a polymerizable phospholipid of the formula (either one of R<1> and R<2> is a polymerizable acyl, and the other is a non-polymerizable acyl; X is a phospholipid polar group) in an A/B molar ratio of 1/(0.1-10), preferably 1/(0.12-8). The polymerizable acyl group in the polymerizable phospholipid includes the residue of a conjugated double bond- having fatty acid, a triple bond-having fatty acid or a terminal double bond- having fatty acid, e.g. the residue of 2,4-octadecadienoic acid or 9-(p- vinylbenzoyl) nonanoic acid. The forming material is processed into lipidal microsomes by a conventional method, preferably an extrusion method, and after the formation of the membrane, the polymerizable phospholipid of the component B is polymerized.
Eight consecutive weekly sessions lasting 40-45 minutes of myofascial release of the trunk physiological chains. The connective tissue of the flexion chain and the posterior static chain will be released. The myofascial release will be obtained through the mechanical effect produced by the friction of the therapist's hand with a surface of the patient's body, which is performed through "traces" executed with the fingers (thumb supported or middle finger on the indicator to achieve effect local) following as addressed chains. The release will be repeated until the feeling of local relaxation of the tissue.
A method includes receiving an initial dataset. Each record of the initial dataset comprises a set of quasi-identifier attributes and a set of non-quasi-identifier attributes. A processor assigns a link identifier to each record and replaces each set of quasi-identifier attributes with a range to form a generalized set. The processor removes duplicate records based on identical generalized sets to generate de-duplicated records. The processor generates a randomized record by replacing the generalized set of each de-duplicated record with a corresponding set of random values. The processor passes the set of random values of each randomized record through multiple hash functions to generate multiple outputs. The multiple outputs are mapped to a Bloom filter. The processor forms a dataset by combining each randomized record with one or more sets of non-quasi-identifier attributes. The set of random values is a fingerprint for a corresponding record of the dataset.
Daratumumab is a humanized antibody against CD38 which is expressed on myeloma cells. Daratumumab exhibited single agent activity in myeloma and is a promising new treatment. Recently, 2 phase 1 / 2 studies establishes the dosing regimen for Daratumumab and impressive single agent activity of about 30% response rates in patients who relapse after prior lenalidomide and bortezomib. Daratumumab also appear to be well tolerated. The most common toxicity is infusion-related and almost all confined to the first cycle. On the whole these are manageable with early intervention, concurrent corticosteroids and anti-histamines as well as slowing infusion rate. More recently, early results from 2 randomise study comparing Daratumumab plus lenalidomide and dexamethasone compared to lenalidomide and dexamethasone, and Daratumumab plus bortezomib and dexamethasone compared to bortezomib and dexamethasone, showed that the addition of Daratumumab significantly improved response and progression free survival, including a high minimal residual disease (MRD) negative rate of more than 20% in the relapse myeloma populations.

In addition, the use of immunomodulatory drugs, such as thalidomide and lenalidomide, has been shown to augment NK cell activity. NK cells are important mediator of antibody dependent cellular cytotoxicity, which is an important mechanism of action for Daratumumab. Furthermore, in the studies using another antibody target SLAMF7, Elotuzumab, the addition of dexamethasone greatly improve efficacy. Furthermore, thalidomide plus dexamethasone combination have a long history in myeloma and is relatively well tolerated and cost-effective. We therefore propose to add Daratumumab to thalidomide and dexamethasone, as this combination will be relatively easy to deliver in the Asian population because of availability and there is good rationale that such a combination will be synergistic and well-tolerated

Patients will be assessed every 28 days (+/-10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first). After disease progression, the treating physician should provide long-term follow-up data on disease status and survival. For patients who discontinued treatment before disease progression occurred, disease assessment measurements shall be performed once every 28 days (+/- 10 days) until disease progression. After patients have documented progression of disease, they will be followed for survival every 3 months (+/-10 days) until study closure or until patients withdraws consent, is lost to follow-up or until death, whichever comes first. For any patient who is lost to follow-up, the study site shall attempt to ascertain survival information via public database search.
The invention belongs to the field of antisense nucleic acid medicaments, and relates to a macrophage inflammatory protein (MIP) 3 alpha antibody to nuclear antigen (ANA) 6 and preparation thereof to the preparation of immunosuppressive medicaments. The immune response of an organism plays a key role in autoimmune diseases and the exclusive reaction of the transplantation of organs and tissues. The invention provides the antisense nucleic acid molecule MIP3 alpha ANA6 used for preparing the immunosuppressive medicaments. The MIP3 alpha ANA6 is a double-stranded nucleic acid molecule. The sense strand of a DNA sequence of the MIP3 alpha ANA6 is 5'-ATATATTGTGCGTCTCCTC-3', and an antisense strand is 5'-GAGGAGACGCACAATATAT-3'. Under the condition of culture with the addition of inflammatory cytokines, the MIP3 alpha ANA6 can remarkably reduce many kinds of cell expressing MIP3 alpha mRNA and generating MIP3 alpha proteins, and functions in immunosuppression by suppressing antigen presenting cells and T cells. The invention provides the novel antisense nucleic acid medicament for treating MIP3 alpha-related immune diseases.
White matter dysplasia (WMD) in preterm infants due to intrauterine inflammation is caused by excessive apoptosis of oligodendrocyte precursor cells (OPCs). In recent years, studies have found that excessive autophagy and apoptosis are highly interconnected and important in infection and inflammatory diseases in general. Therefore, in this study, we aimed to confirm whether regulation of autophagy by using the Akt phosphorylation agonist SC79 can inhibit abnormal apoptosis of OPCs and promote myelin maturation and white matter development in neonatal rats with WMD. We investigated the effect of inflammation on oligodendrocyte development in P0 neonatal rats by intracerebellar injection of LPS, and collected brain tissue at P2 and P5. Immunohistochemical and immunofluorescence staining were used to evaluate white matter damage, while immunofluorescence staining, terminal deoxynucleotidyl transferase dUTP nick end labeling analysis (TUNEL), and western blotting were used to evaluate autophagy and apoptosis. First, we observed that white matter development was arrested and white matter fiber maturation was impaired in LPS-inflicted pups compared with those in the sham-operated group. Second, treatment with SC79 reduced the levels of LC3II, caspase 3, caspase 9, and Bax/Bcl-2 and increased the levels of p62, p-Akt, and p-mTOR in the brain tissue of neonatal rats. Finally, SC79 treatment inhibited OPC apoptosis by increasing the binding of Beclin 1 to Bcl-2, which promoted OPC differentiation and maturation. However, the opposite results were observed after rapamycin administration. Taken together, our results suggest that SC79 can inhibit the abnormal apoptosis of OPCs caused by excessive autophagy through the Akt/mTOR pathway and that SC79 is a potential therapeutic agent for WMD in preterm infants.
Clinical management of whiplash-associated disorders is challenging and often unsuccessful, with over a third of whiplash injuries progressing to chronic neck pain. Previous imaging studies have identified muscle fat infiltration, indicative of muscle weakness, in the deep cervical extensor muscles (multifidus and semispinalis cervicis). Yet, kinematic and muscle redundancy prevent the direct assessment of individual neck muscle strength, making it difficult to determine the role of these muscles in motor dysfunction. The purpose of this study was to determine the effects of deep cervical extensor muscle weakness on multi-directional neck strength and muscle activation patterns. Maximum isometric forces and associated muscle activation patterns were computed in 25 test directions using a 3-joint, 24-muscle musculoskeletal model of the head and neck. The computational approach accounts for differential torques about the upper and lower cervical spine. To facilitate clinical translation, the test directions were selected based on locations where resistance could realistically be applied to the head during clinical strength assessments. Simulation results reveal that the deep cervical extensor muscles are active and contribute to neck strength in directions with an extension component. Weakness of this muscle group leads to complex compensatory muscle activation patterns characterized primarily by increased activation of the superficial extensors and deep upper cervical flexors, and decreased activation of the deep upper cervical extensors. These results provide a biomechanistic explanation for movement dysfunction that can be used to develop targeted diagnostics and treatments for chronic neck pain in whiplash-associated disorders.
Stress and learning co-evolved in parallel, with their interdependence critical to the survival of the species. Even today, the regulation of moderate levels of stress by the central autonomic network (CAN), especially during pre- and post-natal periods, facilitates biological adaptability and is an essential precursor for the cognitive requisites of learning to read. Reading is a remarkable evolutionary achievement of the human brain, mysteriously unusual, because it is not pre-wired with a genetic address to facilitate its acquisition. There is no gene for reading. The review suggests that reading co-opts a brain circuit centered in the left hemisphere ventral occipital cortex that evolved as a domain-general visual processor. Its adoption by reading depends on the CAN's coordination of the learning and emotional requirements of learning to read at the metabolic, cellular, synaptic, and network levels. By stabilizing a child's self-control and modulating the attention network's inhibitory controls over the reading circuit, the CAN plays a key role in school readiness and learning to read. In addition, the review revealed two beneficial CAN evolutionary adjustments to early-life stress "overloads" that come with incidental costs of school under-performance and dyslexia. A short-term adaptation involving methylation of the FKBP5 and NR3C1 genes is a liability for academic achievement in primary school. The adaptation leading to dyslexia induces alterations in BDNF trafficking, promoting long-term adaptive fitness by protecting against excessive glucocorticoid toxicity but risks reading difficulties by disruptive signaling from the CAN to the attention networks and the reading circuit.
PROBLEM TO BE SOLVED: To provide a transdermal plaster preparation raised in transdermal absorbability of physiologically active substance esp. a matrix transdermal plaster preparation. SOLUTION: This transdermal plaster preparation comprises a basic medicinal salt e.g. an antipyretic antiphlogistic analgesic agent and an organic acid salt e.g. sodium acetate having a powder mean particle size of 0.1 to 100 μm. The organic acid salt is blended at a ratio of 0.01 to 15 wt.% based on the total weight of all components of adhesive layer.
Protein diets are required for the normal development of the reproductive system and their inadequacy or deficiency might have hazardous functional complications during maturational and developmental stages. The study was carried out to evaluate the effect of selenium (Se) and zinc (Zn) supplementation on the male and female reproductive organs of rats with postnatal protein malnutrition. Male and female weanling rats were randomly assigned to six groups respectively. The adequate protein diet rats were fed with 16% casein diet while the protein malnourished diet (PMD) rats were fed with 5% casein diet. After the 8th week of feeding, Se (sodium selenite; Na2SeO3) and Zn (zinc sulfate; ZnSO4·7H2O) were supplemented for 3 weeks. The growth curve of body weights, lipid profile, testosterone and progesterone level, Na+-K+-ATPase activity, oxidative stress, and antioxidant status were evaluated. The results showed that PMD reduced the body weights of male and female rats. It also reduced the activities of catalase and glutathione peroxidase in the testes, but reductions in superoxide dismutase and glutathione-S-transferase activities, glutathione, vitamins C and E, testosterone, and progesterone levels were observed in both the testes and ovaries. Furthermore, PMD increased the nitric oxide level in both organs and altered the plasma lipid profiles in both sexes. Se and Zn supplementation, however, restored almost all the alterations observed in all the parameters analyzed. In conclusion, Se and Zn supplementation protects the male and female reproductive organs of rats against postnatal protein malnutrition.
Adverse events were assessed in BI Trial 1100.1032 (ACTG 245), a double-blind, placebo-controlled trial of VIRAMUNE (n=305) in which pediatric patients received combination treatment with VIRAMUNE. In this trial two patients were reported to experience Stevens-Johnson syndrome or Stevens-Johnson/toxic epidermal necrolysis transition syndrome. Safety was also assessed in trial BI 1100.882 (ACTG 180), an open-label trial of VIRAMUNE (n=37) in which patients were followed for a mean duration of 33.9 months (range: 6.8 months to 5.3 years, including long-term follow-up in 29 of these patients in trial BI 1100.892). The most frequently reported adverse events related to VIRAMUNE in pediatric patients were similar to those observed in adults, with the exception of granulocytopenia, which was more commonly observed in children receiving both zidovudine and VIRAMUNE. Cases of allergic reaction, including one case of anaphylaxis, were also reported.

The safety of VIRAMUNE was also examined in BI Trial 1100.1368, an open-label, randomized clinical study performed in South Africa in which 123 HIV-1 infected treatment-naïve patients between 3 months and 16 years of age received combination treatment with VIRAMUNE oral suspension, lamivudine and zidovudine for 48 weeks [see Use In Specific Populations (8.4) and Clinical Pharmacology (12.3)]. Rash (all causality) was reported in 21% of the patients, 4 (3%) of whom discontinued drug due to rash. All 4 patients experienced the rash early in the course of therapy (<4 weeks) and resolved upon nevirapine discontinuation. Other clinically important adverse events (all causality) include neutropenia (8.9%), anemia (7.3%) and hepatotoxicity (2.4%) [see Use in Specific Populations (8.4) and Clinical Studies (14.2)].

Safety information on use of VIRAMUNE in combination therapy in pediatric patients 2 weeks to <3 months of age was assessed in 36 patients from the BI 1100.1222 (PACTG 356) study. No unexpected safety findings were observed although granulocytopenia was reported more frequently in this age group compared to the older pediatric age groups and adults.
BACKGROUND: Opioid use prior to cancer diagnosis increases the likelihood of long-term use during survivorship, however, patterns of use before and after diagnosis are not understood.
METHODS: We used population-based dispensing data linked with cancer and death notifications to identify two cohorts of adults residing in New South Wales initiating opioids within 24 months prior to a first cancer diagnosed between 2014 and 2016: 'survivors' (alive 24 months following diagnosis) and 'decedents' (died within 24 months). We used group-based trajectory modelling to identify trajectories of monthly opioid dispensings and dispensed oral morphine equivalent milligrams (OMEmg) during the 24 months before/after cancer diagnosis.
RESULTS: There were 21,843 survivors with four prediagnosis opioid dispensing trajectories: infrequent (58% of the cohort), late increasing (26%), moderate (10%), and sustained dispensing (6%). We observed an overall increase in dispensed OMEmg of 83 OMEmg (95% CI: 76-91) during the month of diagnosis, with strong opioid formulations comprising most treatment postdiagnosis. Within each prediagnosis opioid trajectory group, we observed five to six postdiagnosis trajectory groups, including no opioid dispensing. Moderate and sustained prediagnosis groups had large proportions of people continuing or increasing opioid dispensing after diagnosis, while small proportions discontinued opioid treatment. We observed similar trajectories in the decedent cohort.
CONCLUSIONS: There is considerable heterogeneity in opioid use before and after cancer diagnosis. Our findings suggest noncancer factors drive a significant proportion of postdiagnosis opioid use, but use increased significantly from the month of cancer diagnosis and never returned to prediagnosis levels.
Non-metallic microparticulate carrier materials for a large and varied group of pharmaceutical and cosmetic agents are disclosed. Microdispersions of such carrier materials charged with at least one such pharmaceutical and/or cosmetic agent are also described. The microdispersions can be formulated for oral, parenteral, topical, inhalation and suppository administration. The formulations have varied uses depending on the pharmaceutical and or cosmetic agent utilized such as for combating microbial, fungal, yeast, viral and the like infections, treating acne, Herpes, burns, dermatoses caused by poisonous plants and irritants, reduction of wrinkles, moisturizing skin, etc. The microparticles are suitably charged particles of silica, alumina, boron, charcoal and the like and have a particle size of about 3 to about 250 μm. The pharmaceutical and cosmetic active materials, which include ozone, vitamins, hormones, steroids, minerals humectants, etc., complex with the microparticles. The liquid carrier for the microparticles include water, propylene glycol, alcohols such as methanol, ethanol and propanols, and dimethyl sulfoxide. The resulting dispersions are believed to be similar to isotonic saline and mimic body fluids which makes the dispersions very physiologically compatible thereby aiding and speeding the delivery of the agents across membranes and to the afflicted tissue. Methods of using these microdispersions and the containing the same are also disclosed.
Systems and methods are disclosed for creating and updating medical records and documents. A user input is received in a first section on an interface comprising unstructured textual data that is associated with a medical record. The user input received in the first section may be utilized to update the medical record preferably without requiring the user to provide an additional second input in a separate section. At least a portion of the unstructured textual data is mapped to one or more attributes associated with a structured format for the medical record. In response to receiving a single data transfer command, an instruction is generated causing a transfer of the unstructured textual data to a second section on the interface associated with the structured format for the medical record. The mapped data is displayed in the second section in accordance with the structured format.
The invention provides a pantoprazole sodium composition for injection. The composition contains pantoprazole sodium and disodium ethylene diamine tetraacetate that are in a proportion of 1:0.02-0.1 by weight. And the composition is prepared by the steps of: 1) liquid medicine preparation: placing pantoprazole sodium and disodium ethylene diamine tetraacetate in a preparation pot, adding water for injection and stirring to make the above agents dissolved and mixed well with the water, adjusting the pH value of the mixture to 10.5-12.5; 2) rubber stopper treatment; 3) aseptic filtration and separate packing; 4) vacuum freeze drying, thus obtaining the composition. For pantoprazole sodium medicaments extremely easy to react with exudates from a rubber stopper, the pantoprazole sodium composition for injection in the invention can simultaneously guarantee the visible foreign matters and insoluble particles in products meeting the requirement of an injection. According to the invention, quality level of the composition product is improved, and the hidden trouble that unqualified visible foreign matters and insoluble particles threat patient clinical medication safety can be avoided. Additionally, the composition of the invention has better curative effects and less clinical side effects.